Table 2.
Actively Recruiting Clinical Trials Evaluating PARP inhibitor combination
| Therapeutics | Indications | Phase | Clinical Trial |
Target |
|---|---|---|---|---|
| Niraparib/Bevacizu mab | Platinum-sensitive Epithelial Ovarian Cancer | I/II | NCT02354131 | VEGFR |
| Niraparib/Pembroli zumab | Triple-negative Breast Cancer or Ovarian Cancer | I/II | NCT02657889 | PD-1 |
| Olaparib/AT13387 | Metastati Solid Tumors/Cannot Be Removed by Surgery/Recurrent Ovarian/Fallopian Tube/Primary Peritoneal/Triple-Negative Breast Cancer | I | NCT02898207 | HSP90 |
| Olaparib/AZD2014/AZD5363 | Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | I/II | NCT02208375 | mTORC1/2 or AKT |
| Olaparib/AZD2281/AZD5363/AZD1775/AZD2014 | Advanced Solid Tumors | II | NCT02576444 | PI3K/AKT, WEE1, mTORC1/2 |
| Olaparib/Cediranib | Time Ovarian Cancer Worsens on Olaparib | II | NCT02340611 | VEGFR1/2/3 |
| Olaparib/Cediranib | Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | III | NCT02446600 | VEGFR1/2/3 |
| Olaparib/Cediranib/MEDI4736 | Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | I/II | NCT02484404 | VEGFR1/2/3, PD-L1 |
| Olaparib/Prexasertib | Advanced Solid Tumors | I | NCT03057145 | CHK1 |
| Olaparib/Tremelimumab | BRCA-deficient Ovarian Cancer | I/II | NCT02571725 | CTLA4 |
| Rucaparib/Atezolizumab | Solid Tumors and Advanced Gynecologic Cancers | II | NCT03101280 | PD-L1 |
| Veliparib/Carboplatin/Paclitaxel | Maintenance Therapy in Newly Diagnosed Stage III or IV High-grade Serous/Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer | III | NCT02470585 | Standard-of-care |
| Veliparib/Dinaciclib | Advanced Solid Tumors (BRCA1/2 mutation) | I | NCT01434316 | CDK12 |
| Veliparib/Floxuridine | Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | I | NCT01749397 | Nucleotide Analog |
| Veliparib/Irinotecan | Stage III, IIIB, IIIC, IV Ovarian Cancer | I | NCT00576654 | Topoisome rase |
| Veliparib/Irinotecan | Cancer That Is Metastatic or Cannot Be Removed by Surgery | I | NCT02484404 | Topoisome rase |
| Veliparib/Liposomal Irinotecan | Malignant Solid Neoplasm | I | NCT02631733 | Topoisome rase |
| Veliparib/Nivolumab | Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed or Lymphoma With or Without Alterations in DNA Repair Genes | I | NCT03061188 | PD-1 |
| Veliparib/Topotecan | Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | I/II | NCT01012817 | Topoisome rase |
| Veliparib/VX-970/cisplatin | Refractory Solid Tumors | I | NCT02723864 | ATR |